Get the Stockscreener App
1.70
1.80%
0.03
Cel-Sci Corp. stock is traded at $1.70, with a volume of 84,383.
It is up +1.80% in the last 24 hours and up +19.72% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$1.67
Open:
$1.7
24h Volume:
84,383
Relative Volume:
0.28
Market Cap:
$29.90M
Revenue:
-
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.4885
EPS:
-3.4798
Net Cash Flow:
$-16.66M
1W Performance:
+14.86%
1M Performance:
+19.72%
6M Performance:
-50.58%
1Y Performance:
-81.09%
1-Day Range:
$1.655
$1.7037
1-Week Range:
$1.47
$1.75
52-Week Range:
$0.89
$10.83
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.70 | 26.21M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
521.50 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.79 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.71 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
972.55 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
191.97 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
CEL-SCI Corp (CVM) Key Financial Ratios – Valuation, Profitability & More - Value Research
CVM|CEL-SCI Corp|Price:1.650|Chg%:+0.040 - TradingKey
Cel Sci CEO Geert Kersten purchases $138,000 in shares By Investing.com - Investing.com Nigeria
CEL SCI (CVM) CEO adds 100K restricted shares to his stake - Stock Titan
Cel-Sci (CVM) Outlook: Ends Up by 3.14% at $1.64 for the Current Session; Key Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseHagopian Line - vinanet.vn
CEL-SCI Company Profile & Introduction - Moomoo
CEL-SCI closes $2.5M offering to fund Multikine - scanx.trade
CEL-SCI Q3 Results: Per-share loss narrows 65% YoY to $(0.47) - scanx.trade
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting - Investing.com
CEL SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI director granted 110K options at $1.49 | CVM Insider Trading - Stock Titan
CEL-SCI (NYSE: CVM) awards CEO 300,000 options over 3 years - Stock Titan
CEL-SCI (NYSE: CVM) awards Cipriano 80K options vesting over 3 years - Stock Titan
CEL-SCI (CVM) awards CSO Talor Eyal 250,000 stock options - Stock Titan
Form 8K CEL-SCI Corp For: 17 August By Investing.com - Investing.com Nigeria
CEL-SCI (NYSEAMERICAN: CVM) CFO lands new 2036 stock option grant - Stock Titan
CEL-SCI (CVM) Advances Multikine Trial Amid Low Valuation and Gu - GuruFocus
CEL-SCI Reports Fiscal Third Quarter 2026 Results - Yahoo Finance
Cel-Sci: Fiscal Q3 Earnings Snapshot - marketscreener.com
CEL-SCI (CVM) faces going concern risk amid $16.6M loss and $6.5M cash - Stock Titan
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Stock News Today - tradingkey.com
CEL-SCI publishes study on Multikine cancer treatment biomarkers - Investing.com
CEL-SCI (CVM) Advances Oral Cancer Immunotherapy Amid Challengin - GuruFocus
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo Finance
CEL-SCI Trial Reports 73% Five-Year Survival in Low PD-L1 Oral Cancer - Stock Titan
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVM|CEL-SCI Corp|Price:1.180|Chg%:+0.010 - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Balance Sheet - TradingKey
TradingKey - TradingKey
CVM|CEL-SCI Corp|Price:1.720|Chg%:+0.105 - TradingKey
Cel-Sci Corporation Q4 2024 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Guidance Range - dars.gov.et
$1.155 | Cel-Sci Corporation (CVM) Stock Price Today - Binance
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer - BioBuzz
CEL-SCI launches confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI (CVM) Initiates Global Study for Multikine in Head and N - GuruFocus
Cancer drug Multikine heads into 212-patient global trial for head and neck tumors - Stock Titan
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVMCel-Sci Corp Latest SEC Filings - Finviz
Form DEF 14A CEL-SCI CORPORATION For: 2 July By Investing.com - Investing.com Nigeria
[ARS] CEL SCI CORP SEC Filing - Stock Titan
Equity plans and pay votes at CEL-SCI (NYSE: CVM) 2026 annual meeting - Stock Titan
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
3.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):